Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.

摘要: Objectives:To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) risperidone] on medication use patterns and costs for individuals with schizophrenia. Methods: Using a large, integrated medical service pharmacy claims database, 244 diagnosed schizophrenia (International Classification Diseases [9th revision]: 295.xx) who switched from (n = 202) 42) were identified. Changes in (1999 values) per patient pre- post-switch period evaluated. McNemar’s tests used compare changes antiparkinsonian, antidiabetic antihyper-lipidaemic agents typical antipsychotics, while Wilcoxon signed rank applied examine costs. Results: After olanzapine, percentage patients using concomitant antiparkinsonian antipsychotics decreased significantly 30.20% 21.29% (p 0.0094) 30.69% 18.32% 0.0006), respectively. There was no significant change antihyperlipidaemic drugs. For mental health-related treatment, annualised pharmaceutical increased by $US1761 (from $US1829 $US3590, p < 0.0001) but $US3511 $US11 292 $US7781, 0.0036), driven primarily lower emergency room care hospital outpatient This resulted overall healthcare Similar results observed total In contrast, after there any medications assessed (mental healthcare-related total), despite decrease Conclusions: Switching associated improved agents. While both health significantly, this not increase These outcomes, however, evidenced risperidone.